Clinical trials: Neoplasia Prostate
Prostate Cancer
Liposomal Doxorubicin and Thermal Therapy in Treating Patients With Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as liposomal doxorubicin, use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00061867
- Testing
- pegylated liposomal doxorubicin hydrochloride, hyperthermia treatment
- Where
- 2 sites in United States
- Sponsor
- Imunon
Prostate Cancer
Real Time MRI Fused to Cone Beam CT Guided Biopsies of the Prostate.
The purpose of this study is to investigate a novel method of prostate biopsy using a computerized guidance system to accurately target lesions within the prostate.
- Trial name
- NCT04180592
- Testing
- CT Fusion + Transrectal U/S Guided Prostate Biopsy
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Queen's University
Metastatic Hormone-sensitive Prostate Cancer
Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer
The purpose of the study is to assess the efficacy and safety of BAY1841788 (darolutamide (ODM-201)) in combination with standard androgen deprivation therapy (ADT) and docetaxel in patients with metastatic hormone sensitive…
- Trial name
- ARASENS (NCT02799602)
- Testing
- BAY1841788 / darolutamide (ODM-201), Standard ADT (androgen deprivation therapy), Docetaxel
- Where
- 322 sites in United States, Australia and 21 more
- Volunteers
- 1,306 people
- Sponsor
- Bayer
Prostate Cancer
Tetrathiomolybdate in Hormone Refractory Prostate Cancer
Purpose: The aim of this clinical trail is to evaluate Tetrathiomolybdate (TM) in the treatment of hormone refractory prostate cancer.
- Trial name
- NCT00150995
- Testing
- Tetrathiomolybdate
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Michigan Rogel Cancer Center
Prostatic Neoplasms
Oral Treatment With BIBF 1120 Together With Docetaxel and Prednisone in Patients With Hormone Refractory Prostate Cancer
The primary objective of this study was to determine the safety and Maximum tolerated dose (MTD) of BIBF 1120 combination therapy with docetaxel and prednisone in patients with hormone refractory prostate cancer.
- Trial name
- NCT02182219
- Testing
- BIBF 1120
- Volunteers
- 21 people
- Sponsor
- Boehringer Ingelheim
Prostate Cancer, Opioid Use
Post-Discharge Opioid Reduction Intervention for Open, Laparoscopic, and Endoscopic Surgery
ORIOLES is a non-randomized, pre-post intervention study designed to improve quality of opioid prescribing and use after discharge for patients undergoing urologic surgery.
- Trial name
- ORIOLES (NCT03536065)
- Testing
- Opioid Reduction Intervention, Current Care
- Where
- United States
- Volunteers
- 443 people
- Sponsor
- Johns Hopkins University
Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone
Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy
This phase I/II trial studies the best dose of M3814 when given together with radium-223 dichloride or with radium-223 dichloride and avelumab and to see how well they work in treating patients with castrate-resistant prostate…
- Conditions
- Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes, Stage IVB Prostate Cancer AJCC v8
- Trial name
- NCT04071236
- Testing
- Avelumab, Biospecimen Collection, Bone Scan
- Where
- 32 sites in United States
- Volunteers
- 90 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Randomized Phase II Trial of Salvage Radiotherapy for Prostate Cancer In 4 Weeks v. 2 Weeks
The purpose of this study is to compare urinary and bowel side effects of hypofractionated radiotherapy in 20 treatments (4 weeks) to ultra-hypofractionated radiotherapy in 5 treatments (2 weeks) for prostate cancer that has…
- Trial name
- NCT04422132
- Testing
- 5 days Radiation Therapy (32.5 Gy in 5 fractions), 20 days Radiation therapy (55 Gy in 20 fractions)
- Where
- United States
- Volunteers
- 137 people
- Sponsor
- Weill Medical College of Cornell University
Prostate Cancer
Imaging Study to Investigate Safety and Diagnostic Performance of 18F rhPSMA 7.3 PET Ligand in Suspected Prostate Cancer Recurrence
A prospective, Phase 3, multi center, single-arm, imaging study investigating the safety and diagnostic performance of rhPSMA 7.3 (18F) Positron Emission Tomography (PET) ligand in men with suspected prostate cancer recurrence…
- Trial name
- NCT04186845
- Testing
- rhPSMA-7.3 (18F) Injection, Positron emission tomography scan
- Where
- 28 sites in United States, Finland and 1 more
- Volunteers
- 391 people
- Sponsor
- Blue Earth Diagnostics
Prostatic Neoplasm
Steps for PRosTAte Cancer Health and Survival (SPaRTACuS): Pilot Study of a Walking Intervention to Improve Health and Quality of Life in Prostate Cancer Patients
The purpose of this study is to determine whether sustainable daily physical activity is effective in improving biological indicators of health and self-reported quality of life in men with prostate cancer.
- Trial name
- NCT01696539
- Testing
- Walking Intervention, Standard of Care
- Where
- Sweden
- Volunteers
- 42 people
- Sponsor
- Örebro University, Sweden
Prostate Cancer
Motorised Probe Holder Assisting Prostate Biopsies
Study, for the first time in clinical conditions, the potential contribution, in terms of accuracy, of the motorised probe holder during prostate biopsies.
- Trial name
- PROSBOT-Apollo (NCT02132975)
- Testing
- Biopsies using Apollo and UroStation®, Biopsies using UroStation® (image fusion)
- Where
- France
- Volunteers
- 20 people
- Sponsor
- AdministrateurCIC
Prostate Cancer
Phase 1 Study to Evaluate PK, Safety, and Tolerability of HRS-5041 in Healthy Caucasian Male Participants
This is a phase 1, open-label, randomized study. The objective of this study is to evaluate the PK, safety and tolerability of orally administered single-dose HRS-5041 in healthy Caucasian male participants.
- Trial name
- NCT06559007
- Testing
- HRS-5041 dose level 1, HRS-5041 dose level 2
- Where
- Australia
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Atridia Pty Ltd.
Prostate Cancer
Neoadjuvant Study of In-situ REIC/Dkk-3 in Prostate Cancer
This is a phase I neoadjuvant gene therapy followed by prostatectomy, open-label, dose-escalation trial for prostate cancer patients with high risk of local recurrence after radical prostatectomy.
- Trial name
- NCT01197209
- Testing
- Ad-REIC/Dkk-3
- Where
- United States
- Sponsor
- Momotaro-Gene Inc.
Prostate Cancer
Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
The primary objective of this study is to evaluate the performance of HR-TRUS in detection of prostate cancer lesions relative to whole mount section after radical prostatectomy as the reference.
- Trial name
- EXACTVU (NCT03679819)
- Testing
- HR-TRUS
- Where
- France
- Volunteers
- 32 people
- Sponsor
- Institut Paoli-Calmettes
Prostate Cancer, Prostate Cancer (Diagnosis)
Study of the Epidemiological, Clinical, Diagnostic, and Therapeutic Characteristics of Prostate Cancers in Algeria
The goal of this observational study is to describe the demographic, epidemiological, clinical, and outcome characteristics of patients with prostate cancer.
- Conditions
- Prostate Cancer, Prostate Cancer (Diagnosis), Prostate Cancer (Post Prostatectomy), Prostate Cancer Patients Treated by Radiotherapy
- Trial name
- CLIQQC (NCT07484971)
- Where
- 24 sites in Algeria
- Volunteers
- 2,000 people
- Sponsor
- Société Algérienne de Formation et Recherche en Oncologie
Prostatic Neoplasms
Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer
Background: Sipuleucel-T is a new treatment for advanced stage prostate cancer. It takes cells from a person with prostate cancer and treats them in the laboratory.
- Trial name
- NCT01420965
- Testing
- CT-011 (Anti-PD1 Antibody), Sipuleucel-T (Provenge), Cyclophosphamide
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Augusta University
Prostate Cancer, Physical Function
RESIST-ADT (Androgen Deprivation Therapy)
The overall goal of this study is to determine if implementing structured exercises prevent decline in muscle mass, muscle strength and physical function in men with prostate cancer undergoing androgen deprivation therapy (ADT).
- Trial name
- NCT04485767
- Testing
- Progressive Resistance Training Exercise, Flexibility and Balance Exercise
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Dana-Farber Cancer Institute
Prostatic Neoplasms, Genital Neoplasms, Male
EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC
This phase II study will investigate the activity and safety of radionuclide 177Lu-PSMA therapy versus 177Lu-PSMA in combination with Ipilimumab and Nivolumab in patients with metastatic castrate resistant prostate cancer (mCRPC).
- Conditions
- Prostatic Neoplasms, Genital Neoplasms, Male, Urogenital Neoplasms, Prostate Cancer
- Trial name
- ANZUP2001 (NCT05150236)
- Testing
- 177Lu-PSMA-617, Ipilimumab, Nivolumab
- Where
- 8 sites in Australia
- Volunteers
- 93 people
- Sponsor
- Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Prostate Cancer
A Trial of CTT1403 for Metastatic Castration Resistant Prostate Cancer
The purpose of this study is to find the highest dose level of study drug, CTT1403, that can be safely administered to patients with metastatic castration resistant prostate cancer (mCRPC).
- Trial name
- NCT03822871
- Testing
- CTT1403, CTT1057, 68Ga-PSMA-11
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Cancer Targeted Technology
Risk of Breast Cancer, Risk of Gynaecological Cancer
Cohort Evaluation of Body Fluids Early Detection of Cancer in High-risk Individuals
LEAH is a prospective, observational, single-centre, non-randomised, open-label study of people at increased risk of cancer or malignant disease.
- Conditions
- Risk of Breast Cancer, Risk of Gynaecological Cancer, Risk of Colorectal Cancer, Risk of Upper Gastrointestinal Cancers
- Trial name
- LEAH (NCT06907095)
- Testing
- biological samples
- Where
- France
- Volunteers
- 5,909 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.